Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Xgeva Gains FDA Nod For Use In Rare Bone Tumor

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of denosumab for giant cell tumor of the bone comes more than a year after Amgen’s failed bid to add a more commercially significant indication for prevention of bone metastases in patients with castrate-resistant prostate cancer.


Related Content

Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals
Xgeva Comes Up Short On Clinical Benefit, Has Too Much Risk, ODAC Tells FDA
FDA Approves Amgen's Denosumab For First Oncology Indication


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts